Slingshot Legal Support is actively assessing claims from patients who have developed severe injuries after using Ozempic and other semaglutide or tirzepatide containing drugs for obesity and chronic weight management. In addition to Ozempic, Rybelsus and Wegovy by Novo Nordisk, Eli Lilly’s Mounjaro, Trulicity and Zepbound are also at issue in this lawsuit. 

Research indicates that many individuals with chronic obesity and diabetes are unaware of their mild gastroparetic conditions until they start using these medications. Thus unbeknownst to many users, these drugs can worsen the symptoms of this condition. Additionally, it has been found that using these medications for weight management can significantly increase the risk of initially developing gastroparesis (aka stomach paralysis), as well as other conditions such as bowel obstruction, esophageal tearing, and cyclical vomiting. 

Although the drug labels caution against potential gastrointestinal side effects, they fall short of fully disclosing the nature and severity of these risks and omit  gastroparesis warnings altogether. Had the patients been fully informed about these significant and concealed risks, they might have chosen not to use these medications.

If you or someone you know may have been harmed by these medications, sign up below for a risk-free consultation with our expert team. Do not hesitate: you deserve full transparency and accountability. We can’t let big pharma off the hook again.